
    
      The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which
      aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in
      platinum-resistant recurrent ovarian cancer.The patient has undergone surgery and received â‰¥2
      lines of platinum-containing chemotherapy.
    
  